S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NASDAQ:ZY

Zymergen (ZY) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$2.43
▼
$2.43
50-Day Range
$2.35
▼
$3.14
52-Week Range
$1.10
▼
$12.42
Volume
85 shs
Average Volume
1.23 million shs
Market Capitalization
$253.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.60
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Zymergen MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
7.0% Upside
$2.60 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.99) to ($2.41) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.97 out of 5 stars

Basic Materials Sector

161st out of 164 stocks

Commercial Physical Research Industry

16th out of 16 stocks

See Top Rated MarketRank™ Stocks Here

ZY stock logo

About Zymergen (NASDAQ:ZY) Stock

Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.

Receive ZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymergen and its competitors with MarketBeat's FREE daily newsletter.

ZY Stock News Headlines

May 23, 2023 | bizjournals.com
Life sciences incubator in Vacaville looks to attract, retain hub's biotechs
May 17, 2023 | marketwatch.com
Nano Robots Market Reports, Scope, Methodology, Timelines And Challenges Forecast Till 2030
June 5, 2023 | Legacy Research (Affiliate) (Ad)
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
May 16, 2023 | technews.tmcnet.com
Prescient Appoints Three New Members to its Board of Directors
May 4, 2023 | marketwatch.com
Nano Robots Market Global Trends, Segmentation and Opportunities Forecast To 2030
April 13, 2023 | marketwatch.com
Organ-On-Chip (OOC) Market Growing Massively by 2023 to 2029 Major Players | Emulate, Mimetas, TissUse, Tara Biosystems
February 22, 2023 | marketwatch.com
Medical AI Data Analysis Market Detailed Analysis of Current Scenario with Growth Forecasts to 2028
February 21, 2023 | marketwatch.com
Global Nanobots/Nanorobots Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report 2023-2028
June 5, 2023 | Legacy Research (Affiliate) (Ad)
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
February 8, 2023 | finance.yahoo.com
Synthetic Biology Market Size to Reach USD 87 Billion in 2030 | Emergen Research
December 15, 2022 | uk.news.yahoo.com
Nanobots Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Type, By Application, By Region
December 8, 2022 | msn.com
Tech layoffs widen: Intel chops hundreds of Northern California jobs
November 11, 2022 | stocknews.com
3 F-Rated Stocks to Sell Now Rather Than Later
October 26, 2022 | finance.yahoo.com
After Ginkgo merger wraps up, 110 job cuts planned at synthetic biology company Zymergen
October 19, 2022 | seekingalpha.com
Ginkgo Bioworks completes acquisition of Zymergen (NYSE:DNA) - Seeking Alpha
October 19, 2022 | prnewswire.com
Ginkgo Bioworks Completes Acquisition of Zymergen - PR Newswire
October 18, 2022 | prnewswire.com
Evozyne Hires Chief Operating Officer to Scale Scientific Operations for Growth - PR Newswire
September 22, 2022 | fool.com
Cathie Wood Is Loading Up on These 3 Stocks: Should You? - The Motley Fool
September 21, 2022 | stockhouse.com
2022-09-20 | NDAQ:ZY | Press Release | Zymergen Inc. - Stockhouse
September 9, 2022 | finance.yahoo.com
Zymergen Inc. (ZY)
September 8, 2022 | stockhouse.com
2022-09-08 | NDAQ:CYBE | Press Release | CyberOptics Corporation - Stockhouse
September 7, 2022 | bizjournals.com
Five things you need to know today, and text is the new email - Boston Business Journal - The Business Journals
September 6, 2022 | bizjournals.com
Cash burn, lack of profitability stalled Zymergen plans ahead of Ginkgo merger deal - San Francisco Business Times - The Business Journals
September 6, 2022 | finance.yahoo.com
Zymergen's problems were evident to board shortly after IPO, SEC filings show
August 30, 2022 | benzinga.com
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, ZY, FBMS, PBFX - Benzinga
August 26, 2022 | globenewswire.com
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, ZY - GlobeNewswire
August 26, 2022 | finance.yahoo.com
Last of Zymergen's 3 founders to leave as synbio company preps for merger with 80 more layoffs
See More Headlines


ZY Company Calendar

Today
6/05/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Commercial physical research
Sub-Industry
N/A
Sector
Basic Materials
Current Symbol
NASDAQ:ZY
CUSIP
N/A
CIK
1645842
Web
www.zymergen.com
Phone
415-801-8073
Fax
N/A
Employees
502
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.60
High Stock Price Forecast
$2.60
Low Stock Price Forecast
$2.60
Forecasted Upside/Downside
+7.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-361,790,000.00
Net Margins
-2,508.94%
Pretax Margin
-2,508.42%
Return on Equity
-93.37%
Return on Assets
-61.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.59
Quick Ratio
4.47

Sales & Book Value

Annual Sales
$16.74 million
Price / Sales
15.15
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.99 per share
Price / Book
0.61

Miscellaneous

Outstanding Shares
104,355,000
Free Float
92,145,000
Market Cap
$253.58 million
Optionable
Not Optionable
Beta
1.69

Key Executives

  • Ms. Enakshi Singh (Age 44)
    Chief Financial Officer
    Comp: $390.3k
  • Mr. Dmitriy Ryaboy
    Chief Technology Officer
  • Mike Dulin
    Director of Communications
  • Mr. Lincoln Germain
    Chief Commercial Officer
  • Mr. Subodh S. Deshmukh
    Chief Devel. Officer
  • Mr. Devin Scannell
    Sr. VP of Drug Discovery
  • Mr. Duane Valz J.D.
    Sec.
  • Ms. Mina Kim (Age 48)
    Corp. Sec.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













ZY Stock - Frequently Asked Questions

Should I buy or sell Zymergen stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymergen in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ZY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZY, but not buy additional shares or sell existing shares.
View ZY analyst ratings or view top-rated stocks.

What is Zymergen's stock price forecast for 2023?

1 Wall Street research analysts have issued 1 year price objectives for Zymergen's shares. Their ZY share price forecasts range from $2.60 to $2.60. On average, they predict the company's share price to reach $2.60 in the next year. This suggests a possible upside of 7.0% from the stock's current price.
View analysts price targets for ZY or view top-rated stocks among Wall Street analysts.

What is Joshua Hoffman's approval rating as Zymergen's CEO?

64 employees have rated Zymergen Chief Executive Officer Joshua Hoffman on Glassdoor.com. Joshua Hoffman has an approval rating of 62% among the company's employees. This puts Joshua Hoffman in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 58.0% of employees surveyed would recommend working at Zymergen to a friend.

When did Zymergen IPO?

(ZY) raised $401 million in an IPO on Thursday, April 22nd 2021. The company issued 13,600,000 shares at a price of $28.00-$31.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen, UBS Investment Bank and Lazard served as the underwriters for the IPO.

What is Zymergen's stock symbol?

Zymergen trades on the NASDAQ under the ticker symbol "ZY."

What is Zymergen's stock price today?

One share of ZY stock can currently be purchased for approximately $2.43.

How much money does Zymergen make?

Zymergen (NASDAQ:ZY) has a market capitalization of $253.58 million and generates $16.74 million in revenue each year. The company earns $-361,790,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

How many employees does Zymergen have?

The company employs 502 workers across the globe.

How can I contact Zymergen?

The official website for the company is www.zymergen.com. The company can be reached via phone at 415-801-8073 or via email at investors@zymergen.com.

This page (NASDAQ:ZY) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -